| **Visit 17 (Follow-Up Safety Contact and Termination Visit)** | | |
| --- | --- | --- |
| **Procedures** | | **Staff**  **Initials** |
|  | Confirm identity and PTID. |  |
|  | Review/update locator information per site SOPs. |  |
|  | Document any adverse events: Complete/update AE Log CRF(s) as needed. If indicated, schedule interim visit for follow-up of identified AEs. |  |
|  | Provide and explain available exam and lab test results. If STI/RTI/UTI is diagnosed, provide or refer for treatment. Document provision of results, treatments and referrals in chart notes. |  |
|  | Reinforce site contact information and:   * If applicable, schedule a final study visit/contact for disclosure of all remaining exam and lab test results. * If applicable, schedule clinically indicated follow-up for subset of ongoing AEs at this visit. * Inform the participant of planned methods and timeframes for dissemination of study results. * Determine and document whether participant is willing to be contacted about future studies for which s/he may be eligible. |  |
|  | Provide reimbursement. |  |
|  | Ensure that data is entered into the study database (and perform QC2 review, if applicable) ensuring all data entered into the study database is accurate and complete.  **Required Visit Forms:**   * Follow-up Y/N * Follow-up Visit Summary * Study Discontinuation   **Log CRFs (if newly-completed or updated)**   * Adverse Event Summary/Log * Concomitant Medications Summary/Log * Protocol Deviation Summary/Log * Pregnancy Outcome Summary/Log (female participants only) |  |

**Additional Notes/Comments/Referrals:**